AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-84088951/cytrx-s-receives-1m.html" title="Facts and information about CytRx s receives $1M milestone payment from Merck for TranzFect license.(Brief Article)">CytRx s receives $1M milestone payment from Merck for TranzFect license.(Brief Article)</a>
Close
Set up an RSS feed that alerts you when new articles from Vaccine Weekly are available.
Frequently asked questions about RSS feeds
CytRx s receives $1M milestone payment from Merck for TranzFect license.(Brief Article)
1902 MAR 27 - (NewsRx.com & NewsRx.net) -- CytRx Corp. (CYTR) announced that it has received a $1 million milestone payment due from Merck & Co., Inc., pursuant to Merck's license of CytRx's TranzFect technology.
CytRx's TranzFect technology is incorporated in an experimental DNA-based HIV vaccine being developed by Merck & Co., Inc., that has now entered phase I clinical trials. Merck's initiation of this study triggered the milestone fee payable to CytRx.
Merck scientists hope the clinical trials will lead to the development of an HIV vaccine that can effectively prevent, or attenuate, the development of AIDS resulting from HIV infection, as well as help treat HIV ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- CytRx Receives $2 Million Initial Fee Under TranzFect License to Merck.
- Press release article from: PR Newswire December 4, 2000 700+ words
...from Merck & Co., Inc. pursuant to Merck's license of CytRx's TranzFect technology. On November 1...exclusive, worldwide license agreement with Merck whereby CytRx granted to Merck rights to use its TranzFect technology in DNA...
- Merck & Co. Presents Preclinical Data on HIV Vaccine Program Utilizing CytRx's...
- Press release article from: PR Newswire April 2, 2001 700+ words
...PRNewswire/ -- CytRx Corporation (Nasdaq...that scientists from Merck & Co., Inc...In November 2000, Merck licensed from CytRx the right to use CytRx...regimens tested by Merck incorporated CytRx's CRL-1005 compound...
- CytRx Announces First Licensing Agreement With Merck & Co., Inc. For TranzFect...
- Press release article from: PR Newswire November 6, 2000 700+ words
...PRNewswire/ -- CytRx Corporation (Nasdaq...license agreement with Merck & Co., Inc...President and CEO of CytRx. "We look forward to working with Merck and other prospective...technology." About CytRx Corporation CytRx Corporation...
- Merck Publishes HIV Studies Utilizing CytRx's Tranzfect Technology; Results of...
- Press release article from: PR Newswire January 24, 2002 700+ words
ATLANTA -- CytRx Corporation today announced that scientists from Merck & Co., Inc. published...CRL-1005, a component of CytRx's TranzFect technology. In November 2000 Merck licensed from CytRx the right to use TranzFect...
- CytRx's Tranzfect Technology Enters Phase I Clinical Trials As Part of Merck's...
- Press release article from: PR Newswire February 12, 2002 700+ words
ATLANTA -- CytRx Corporation today announced...vaccine being developed by Merck & Co., Inc. that...infection. In November 2000, Merck licensed the right to use CytRx's TranzFect technology...diseases, including HIV. Merck's initiation of the...
- CytRx Reports 2001 Financial Performance; Reports Positive Cash Flow for Year.
- Press release article from: PR Newswire March 26, 2002 700+ words
...signature payment by Merck & Co...of TranzFect. CytRx reported positive...reinvigoration of CytRx in 2002 and beyond...the license to Merck in 2000, we now...based vaccines. CytRx has licensed TranzFect to Merck & Co...
- CytRx Corporation Announces Investment Banking Agreement With Sands Brothers.
- Press release article from: PR Newswire October 8, 2002 700+ words
...a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts...RNA) have been licensed to Vical, Incorporated. CytRx has a research pipeline in the areas of muscular...
- CytRx Meets All Compliance Requirements to Continue Nasdaq Listing.
- Press release article from: PR Newswire May 6, 2003 700+ words
...a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts...RNA) have been licensed to Vical, Incorporated. CytRx's technologies also have potential applications...
- CytRx Establishes Landmark Alliance With The University of Massachusetts...
- Press release article from: PR Newswire April 21, 2003 700+ words
...a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts...RNA) have been licensed to Vical, Incorporated. CytRx's technologies also have potential applications...
- CytRx Reports Third Quarter Financial Results.
- Press release article from: PR Newswire November 20, 2002 700+ words
...a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts...RNA) have been licensed to Vical, Incorporated. CytRx also has a technology portfolio with potential opportunities...
Source: HighBeam Research, CytRx s receives $1M milestone payment from Merck for TranzFect...